NCT02730871 - Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® | Biotech Hunter

Enrollment

173

Participants

Timeline

Start Date

June 24, 2016

Primary Completion Date

July 13, 2018

Study Completion Date

July 13, 2018

Conditions

Open-angle GlaucomaOcular Hypertension

Interventions

DRUG

Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

DRUG

Brinzolamide/brimonidine vehicle

Inactive ingredients used as placebo comparator

DRUG

Travoprost 0.004%/timolol 0.5% solution

1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase

Trial Locations (1)

76134

Contact Alcon for Locations (Europe, Asia, and Latin America), Fort Worth